Atlas Trials

Carmot Therapeutics, Inc.

7 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Carmot Therapeutics, Inc.

RecordFirmDate
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus (NCT06628362)Carmot Therapeutics, Inc.2024-11-21
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity (NCT06525935)Carmot Therapeutics, Inc.2024-08-16
A Study of CT-868 in Type 1 Diabetes Mellitus (NCT06062069)Carmot Therapeutics, Inc.2023-10-19
A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes (NCT05794581)Carmot Therapeutics, Inc.2023-03-21
A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus (NCT05110846)Carmot Therapeutics, Inc.2022-02-22
A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose (NCT04973111)Carmot Therapeutics, Inc.2021-07-16
A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus (NCT04838405)Carmot Therapeutics, Inc.2021-04-29

Track Carmot Therapeutics, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.